Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies and cytokines for cancer and autoimmune diseases, will announce its fourth-quarter and full-year 2022 financial results on February 23, 2023, after market close. A conference call to discuss these results and provide a corporate update will occur the same day at 4:30 p.m. ET. The live webcast will be available in the Investors section of their website and archived for 30 days. Xencor has over 20 candidates in clinical development and three marketed medicines through partnerships, utilizing its XmAb technology for novel therapeutic mechanisms.

Positive

• More than 20 candidates in clinical development.
• Three XmAb medicines marketed by partners.

Negative

• None.

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after the market closes on Thursday, February 23, 2023.

Xencor management will host a conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

The live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at investors.xencor.com and will be archived for at least 30 days. Active participants in the conference call may receive credentials for telephone access by registering at the following link: https://register.vevent.com/register/BI70c60751330540e3909534dca3801239.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb^® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a proteins structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230216005743/en/

Charles Liles

cliles@xencor.com

626-737-8118

Source: Xencor, Inc.

FAQ

What are Xencor's financial results release dates for 2022?

Xencor will report its financial results for the fourth quarter and full year 2022 on February 23, 2023, after market close.

When is Xencor's conference call to discuss financial results?

Xencor's conference call to discuss financial results will be held on February 23, 2023, at 4:30 p.m. ET.

Where can I find Xencor's webcast for financial results?

The live webcast for Xencor's financial results will be available under 'Events & Presentations' in the Investors section of their website.

How many candidates is Xencor developing?

Xencor is developing more than 20 candidates in clinical development.

What technology does Xencor use for its drug development?

Xencor utilizes its XmAb technology, which allows for engineered antibodies with new therapeutic mechanisms.